News
Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) saw its stock climb 2.7% after announcing FDA approval and the U.S. launch of its generic version of Saxenda (liraglutide injection). This marks the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback